Skip to main content

Vaginal and Topical Estrogen

Vaginal and topical estrogen is a cornerstone of genitourinary syndrome of menopause (GSM) management, with its most evidence-based urologic applications being prevention of recurrent UTIs and treatment of vulvovaginal symptoms. For coexisting OAB, local estrogen is an optional adjunct under AUA/SUFU/AUGS 2025 expert opinion[30].[1][2] FDA labeling revisions began with a November 2025 request and the first six product approvals on February 12, 2026; check the current label of the prescribed product.[3]

For related topics, see Vaginal DHEA (prasterone), Ospemifene, Preoperative hormonal priming, the clinical GSM article, Urethral Bulking Agents, and UTI suppressive & prophylactic therapy.

Why vaginal estrogen matters in urology​

The vagina and lower urinary tract are estrogen-responsive tissues; their embryologic origins are not identical. ERα and ERβ are expressed in vaginal epithelium, urethra, trigone, detrusor, pelvic-floor musculature, and endopelvic fascia.[4][5]

Menopausal hypoestrogenism is associated with:

  • Vaginal epithelial thinning (loss of superficial cells, rise in parabasal cells)
  • Vaginal pH 3.5–4.5 to 5.0–7.0 with loss of Lactobacillus dominance, followed by uropathogen colonization (E. coli, Enterobacteriaceae)
  • Urethral mucosal atrophy, which may contribute to urinary symptoms; SUI remains multifactorial
  • Decreased periurethral blood flow and mucosal-barrier impairment
  • Urgency, frequency, and nocturia, which require assessment for other causes
  • Increased susceptibility to UTI[4][6][7]

Vaginal estrogen can improve local estrogenization by restoring epithelial thickness, normalizing pH, re-establishing Lactobacillus dominance, and improving periurethral tissue quality.[8][9]

Formulations and dosing​

All FDA-approved formulations; systemic absorption varies substantially by product and dose.

FormulationBrandActiveDoseScheduleSystemic absorption
Vaginal creamEstraceEstradiol 0.01%0.1 mg/g2–4 g daily × 1–2 wk, then half that dose for a similar period → maintenance 1 g 1–3×/wk (labeled range; the AUA rUTI table uses 2 g daily × 2 wk → 1 g 2–3×/wk)[1][36]Moderate (dose-dependent)
Vaginal creamPremarinConjugated estrogen 0.625 mg/g0.5–2 g for atrophic vaginitis (dose individualized)Daily for 21 days, then 7 days off; dyspareunia: 0.5 g twice weekly or 21 days on/7 off. The AUA rUTI table lists 0.5 g daily × 2 wk → 0.5 g twice weekly[1][33]Dose-dependent
Vaginal insert / tabletVagifem / YuvafemEstradiol10 µgDaily × 2 wk → 2×/wk[37]Very low
Vaginal insertImvexxyEstradiol4 µg or 10 µgDaily × 2 wk → 2×/wkUltra-low (4 µg — lowest of all formulations); label start dose is 4 µg, and the label indication is dyspareunia due to menopause[38]
Vaginal ringEstringEstradiol 2 mg ring releasing 7.5 µg/day—Insert; replace every 90 days[39]Very low
Vaginal insertIntrarosaPrasterone (DHEA) 6.5 mg—Nightly[34]Measurable serum prasterone increase, with slight estradiol and testosterone increases[34] — see Vaginal DHEA
Oral SERMOsphenaOspemifene 60 mg—Daily with food[35]Systemic (oral) — see Ospemifene

Systemic absorption principles:[9][10]

  • Serum estradiol with the 10 µg tablet (about 3–11 pg/mL), 4 µg / 10 µg inserts (3.6 and 4.6 pg/mL versus 4.3 with placebo at day 14) and the 7.5 µg/day ring (5–10 pg/mL) stays within or near the postmenopausal range (NAMS 2020); ACOG 2021 groups the 4 µg insert, 7.5 µg ring and 10 µg tablet/insert as associated with levels below 20 pg/mL[12][29]
  • Circulating estrogen rises transiently with the first application on atrophic tissues, then normalizes within 2–12 weeks as epithelium thickens and absorption decreases
  • Cream absorption is variable and less well characterized: the user measures the dose, and the available serum data come from older, higher-dose studies with less sensitive assays; inserts and rings deliver a fixed low dose[12]
  • Labeled steady-state estradiol is about 5.5 pg/mL (Vagifem 10 µg, day 83) and 7–8 pg/mL (Estring, weeks 12–48); Imvexxy 4 µg and 10 µg averaged 3.6 and 4.6 pg/mL on day 14 versus 4.3 pg/mL with placebo[37][38][39]
  • The 4 µg insert has not been studied for rUTI prevention (AUA rUTI 2025 Table 5 footnote)[1]

Recurrent UTI prevention — the strongest urologic indication​

Guidelines​

  • AUA/CUA/SUFU 2025 : recommend vaginal estrogen for peri- and postmenopausal patients with recurrent UTI when appropriate and without a contraindication.[1] The panel found no formulation clearly superior and advises using the patient's preferred product; it notes that a Cochrane review suggested cream may prevent UTI better than the ring. Systemic estrogen is not recommended for rUTI, and women already on systemic estrogen should still receive vaginal estrogen.[1]
  • AUA/SUFU/AUGS GSM 2025: recommends local low-dose vaginal estrogen for GSM with recurrent UTI ; for GSM with comorbid conditions such as OAB it is an option .[30]
  • AGS Beers Criteria alternatives panel (2025): "First-line preventive therapy for recurrent UTIs in most older women is vaginal estrogen." It explicitly recommends against systemic estrogen for this indication.[11]
  • NAMS 2020 GSM Position Statement. Small RCTs of vaginal estrogen (conjugated estrogen cream, estriol cream, low-dose estradiol ring) reduced recurrent UTI frequency in postmenopausal women.[12]

Evidence​

StudynDesignFinding
Chen 2021 meta-analysis1,936 total (vaginal-estrogen trials)5 RCTsRR 0.42 (95% CI 0.30–0.59) for rUTI reduction with vaginal estrogen; oral estrogen showed no statistically significant benefit (RR 1.11; 95% CI 0.92–1.35)[13]
AUA rUTI 2025 evidence review4 RCTs (n=313); 5 with an added 35-woman trialGuideline systematic reviewFour earlier trials: RR 0.59 (95% CI 0.35–1.01; I² 76%), not significant. Adding the 35-woman Ferrante trial (published online in 2019; print issue 2021), which the guideline rated at high risk of bias: RR 0.58 (95% CI 0.39–0.87). Strength of evidence low[1]
Tan-Kim 20235,638Retrospective before-after cohort, Kaiser Permanente (no control group)UTI frequency 3.9 → 1.8/year (51.9% reduction, p <0.001); 31.4% had zero UTIs in the following year[14]

Predictors of persistent UTIs despite vaginal estrogen (Tan-Kim 2023): age ≥75, higher baseline UTI frequency, urinary incontinence, urinary retention, diabetes.[14]

TAPER trial (July 2026). In 114 postmenopausal participants, twice-weekly periurethral estradiol cream (0.5 g) was noninferior to intravaginal applicator delivery (1 g) for six-month UTI-free status: 50.9% versus 52.6% (difference −1.75 percentage points, 95% CI −20.0 to 17.0). This single-center, unblinded trial used a 25-percentage-point noninferiority margin. It supports discussing an application alternative when applicator use is difficult.[32]

Mechanism — microbiome restoration​

Srinivasan 2022 secondary analysis of an RCT (JAMA Netw Open): in a 144-woman microbiome analysis subset of the 302-person parent trial, after 12 weeks of vaginal estradiol tablets, 80% of analyzed estradiol-arm women had Lactobacillus / Bifidobacterium-dominant vaginal communities versus 36% with a low-pH moisturizer and 26% with placebo (p <0.001); median pH was 5 versus 6 with placebo.[9]

Shen 2016 (low-dose estrogen in atrophic vaginitis) showed rising Lactobacillus and falling Gardnerella with a lower vaginal pH.[15] Moore 2024 (22 women with SUI on estriol cream, before-after, no control) found that women with a Lactobacillus-deficient baseline improved most (pH fell about 1.3 points; p = 0.004), while Lactobacillus-dominant women stayed stable.[7] Microbiome shift is the proposed mechanism; these studies did not measure UTI outcomes.

See UTI suppressive & prophylactic therapy and Non-antibiotic UTI prevention for the broader rUTI framework.

Urgency / urge urinary incontinence​

Vaginal estrogen may improve some urinary symptoms when GSM coexists, but benefit is inconsistent across outcomes. Systemic estrogen can worsen incontinence.[30][10][16]

  • Christmas 2023 systematic review. Vaginal estrogen improves dysuria, frequency, urge incontinence, and SUI; systemic HT may cause or worsen UI.[16]
  • IUGA Committee Opinion. Vaginal estrogen has beneficial effects on UI symptoms versus placebo .[5]
  • EAU non-neurogenic female LUTS 2026: offer vaginal oestrogen to women with LUTS and associated GSM symptoms . The evidence is mainly from SUI and mixed populations and is hard to generalize to predominant OAB/UUI.[40]
  • NICE NG123: offer vaginal oestrogen to women with OAB symptoms and genitourinary symptoms or signs of menopause (1.4.37), and do not offer systemic hormone replacement therapy to treat urinary incontinence (1.4.36).[41]
  • Harncharoenkul 2026 RCT (n = 86, 17β-estradiol 10 µg versus placebo): overall storage-symptom improvement did not show a statistically significant difference at 12 weeks (IRR 1.28, 95% CI 0.57–1.98; p = 0.441). A secondary UUI bother score was lower with estradiol at 4 and 12 weeks (mean differences −1.99 and −1.79; p = 0.013 at each visit), while symptom-severity subgroup analyses did not show a significant difference. The trial also reported improved urethral maturation index and lower vaginal pH.[17]

The WHI versus vaginal contrast: WHI oral CEE increased incontinence. Systemic and local routes have fundamentally different effects on the lower urinary tract; systemic appears to act via counter-productive effects on collagen metabolism and vascular tone.[10][16]

Stress urinary incontinence​

EAU 2026 strongly recommends offering vaginal oestrogen to postmenopausal women with SUI and vulvovaginal atrophy symptoms, citing short-term SUI improvement (LE 1a).[40] Weber's 2015 systematic review concluded that topical estrogen seems to decrease OAB and UI complaints.[18] Rahn 2023 preoperative RCT in prolapse patients found resolved or improved SUI at the preoperative visit in 16/32 (50%) estrogen users versus 9/21 (43%) placebo users with at least moderately bothersome SUI at baseline (p = 0.78; median preoperative interval about 7 weeks).[19]

Pelvic organ prolapse​

Vaginal estrogen has not established improved anatomical repair durability. In the 2026 EVA multicenter trial, perioperative vaginal oestriol improved 12-month patient-reported outcome (PGI-I improvement 97/106 vs 83/104), while anatomical and composite surgical outcomes did not differ significantly.[46] See the priming hub for results and limitations.

  • Taithongchai 2023 Cochrane review. Little to no difference in subjective or objective POP improvement when estrogen was added to surgery; possible fewer postoperative UTIs, with heterogeneous contributing studies and uncertain overall conclusions.[20]
  • IUGA Committee Opinion. Definitive evidence on local estrogen and POP prevention or treatment is lacking.[5]
  • NICE NG123: consider vaginal oestrogen for women with prolapse and genitourinary symptoms or signs of menopause (1.7.3), and an oestrogen-releasing ring when cognitive or physical impairment makes pessaries or creams hard to use (1.7.4). NICE found no evidence on oestrogen for treating prolapse itself.[41]

Perioperative use is covered in Preoperative hormonal priming. The IMPROVE trial (Rahn 2023) found improved objective estrogenization signs among study-cream-adherent participants after a median of about 7 preoperative weeks, but subjective symptom improvement was inconclusive.[19]

Perioperative use in urologic / gynecologic surgery​

Commonly prescribed preoperatively before:

  • Pelvic reconstructive surgery (prolapse repair, slings)
  • Vaginal hysterectomy
  • Anti-incontinence procedures

Rationale: improve tissue quality, vascularity, and wound healing, though high-quality evidence for improved surgical outcomes is limited.[19][20] EAU 2026 rates neoadjuvant or adjuvant local oestrogen as ineffective for improving outcomes of mid-urethral sling surgery (LE 2b).[40] NICE suggests topical oestrogen cream as non-surgical management of a single vaginal mesh exposure smaller than 1 cm², with follow-up within 3 months.[41] See Preoperative hormonal priming.

Non-estrogen hormonal alternatives​

For detail, see the dedicated articles: Vaginal DHEA and Ospemifene. In brief:

AgentRouteKey features
Prasterone (Intrarosa)Vaginal 6.5 mg nightlyConverted to estrogens and androgens; small serum increases occur. FDA-approved for menopausal VVA-related moderate-to-severe dyspareunia[34][10][21]
Ospemifene (Osphena)Oral 60 mg daily with foodSERM with endometrial agonist activity and boxed endometrial/cardiovascular warnings;[35] FDA-approved for moderate-to-severe dyspareunia and vaginal dryness; ACOG Level A alternative to vaginal estrogen for GSM dyspareunia[21][22][23]

Safety​

Endometrial safety​

  • Low-dose vaginal estrogen generally does not require added progestogen. AUA/SUFU/AUGS 2025 recommends counseling that local low-dose vaginal estrogen does not increase the risk of endometrial hyperplasia with atypia or endometrial cancer . It advises against surveillance solely because of local low-dose estrogen, DHEA, or ospemifene use; symptoms and other risk factors still require evaluation.[10][30]
  • Long-term (>1 year) endometrial safety data are limited for vaginal estrogen, vaginal DHEA, and ospemifene
  • Postmenopausal bleeding always warrants evaluation with endometrial biopsy and/or TVUS[10]

Breast cancer safety — reassuring observational data with remaining uncertainty​

SourcenFinding
Beste 2025 meta-analysis8 observational studies; 24,060 for recurrenceVaginal estrogen not associated with increased breast cancer recurrence (pooled unadjusted OR 0.48; 95% CI 0.23–0.98), BC mortality (OR 0.60; 95% CI 0.18–1.95) or overall mortality (OR 0.46; 95% CI 0.42–0.49)[25]
McVicker 2024 JAMA Oncology49,237No increase in breast-cancer-specific mortality versus HRT nonusers (HR 0.77; 95% CI 0.63–0.94)[26]
Agrawal 2023 US claims analysis42,113 total; 5% received vaginal estrogenNo statistically significant difference was detected in a claims-defined recurrence proxy (mastectomy, radiation, chemotherapy, or secondary malignancy 3 months to 5 years after initiation): RR 1.03 (95% CI 0.91–1.18); ER-positive subgroup RR 0.94 (95% CI 0.77–1.15). These outcomes were not adjudicated tumor recurrences.[27]
Cold 2022 Danish cohortPostmenopausal women with early-stage ER-positive breast cancerVaginal estrogen was not associated with recurrence overall (adjusted RR 1.08; 95% CI 0.89–1.32); in the adjuvant aromatase-inhibitor subgroup it was (adjusted RR 1.39; 95% CI 1.04–1.85); no increased mortality was observed[28]

For the July 2026 VEMORA randomized symptom study and its limitations, see GSM in breast cancer survivors.

Guideline positions in breast cancer survivors:

  • ACOG 2021 clinical consensus. Nonhormonal methods are first-line; if they fail, low-dose vaginal estrogen may be used after risk-benefit discussion in breast cancer survivors, including those on tamoxifen, with shared decision-making with the patient and oncologist for AI users[29]
  • AUA/SUFU/AUGS 2025. Low-dose vaginal estrogen may be recommended in the context of multidisciplinary shared decision-making , and clinicians should tell patients there is no evidence linking it to breast cancer development. Data on aromatase-inhibitor users are scarce; the 10 µg tablet, 4 µg insert or low-dose ring may have lower absorption and be preferable[30]
  • AUA rUTI 2025. Vaginal estrogen has not been shown to increase cancer recurrence; consider it for UTI prevention in women with a breast cancer history in coordination with the oncologist[1]
  • Product labeling. FDA warnings changed through product-specific approvals.[3]

Cardiovascular and thromboembolic safety​

In the WHI observational cohort of 45,663 postmenopausal women not using systemic estrogen (median follow-up 7.2 years), vaginal cream or tablet use was not associated with elevated CHD, stroke, or PE/DVT rates compared with nonuse.[45] The WHI findings of increased CV risk applied to oral systemic CEE, not to vaginal preparations.[10][31]

FDA regulatory update — November 2025 to February 2026​

FDA requested changes in November 2025, then approved the first six products on February 12, 2026, removing cardiovascular disease, breast cancer, and probable dementia statements from their boxed warnings. This was not simultaneous removal of every warning from every estrogen product. Use the actual product label for contraindications and counseling.[3]

The American Urogynecologic Society (AUGS) issued a practice advisory in December 2025, before FDA action was final, supporting removal of the boxed warning from topical low-dose vaginal estrogen. It states that clinicians should feel confident offering topical low-dose vaginal estrogen for GSM and recurrent UTI, with shared decision-making that emphasizes the safety data and minimal systemic absorption.[42]

Labeled contraindications vary by product and label revision. Labels for Vagifem (updated 2/2025), Glenmark estradiol vaginal inserts (updated 10/2025), Imvexxy (updated 9/2025), and Premarin vaginal cream (revised 4/2025) carry boxed warnings and list breast cancer or a history of it among the contraindications.[33][37][38][43] The revised Estring label (4/2026) has no boxed warning and lists known or suspected estrogen-dependent neoplasia instead.[39] Check the current label of the specific product. Contraindications across these labels include undiagnosed abnormal genital bleeding; breast cancer or a history of it (Premarin, Vagifem and Imvexxy labels); estrogen-dependent neoplasia (including Estring); active or prior DVT/PE; active or prior arterial thromboembolic disease (stroke, MI); hepatic impairment or disease; known thrombophilia (protein C, protein S or antithrombin deficiency); and hypersensitivity.[33][37][38][39]

Practical prescribing​

Choosing a formulation​

SituationPreferred
UTI prevention (general)AUA/CUA/SUFU 2025 recommends vaginal estrogen for rUTI and advises the patient’s preferred formulation; it notes that the 4 µg estradiol formulation has not been studied for rUTI prevention[1]
Patient convenience / adherenceVaginal ring (Estring) — 90-day replacement; useful when applicator or cream use is difficult (NICE suggests an oestrogen-releasing ring for women with pelvic organ prolapse and menopausal genitourinary symptoms whose cognitive or physical impairment makes vaginal oestrogen pessaries or creams difficult to use). The Estring label cautions that a narrow or stenosed vagina, prolapse, or vaginal infection can increase irritation or ulceration; treat infection before insertion, remove the ring if infection develops, and consider leaving the ring out until erosion or ulceration heals to prevent adherence to the vaginal wall, which has sometimes required surgical removal.[39][41]
Low-dose fixed delivery4 µg insert (Imvexxy) or 7.5 µg/day ring (Estring) are fixed-dose options with low serum estradiol in product studies[10][30][38][39]
Breast cancer survivor (on AI)Individualized low-dose product and shared decision with oncology; no universal safety ranking[28][30]
Prefers oral therapy for moderate-to-severe menopausal vaginal dryness or dyspareuniaOspemifene 60 mg daily with food; review its boxed endometrial and cardiovascular warnings and breast-cancer precaution.[23][35]
Menopause-related moderate-to-severe dyspareunia; prefers a non-estrogen active ingredientPrasterone 6.5 mg nightly; estrogen is a metabolite, and the product has not been studied in women with a breast-cancer history.[34]

Duration of therapy​

GSM is a chronic progressive condition; symptoms recur on discontinuation. NAMS advises continuing therapy as long as needed for symptom control, absent contraindications; endometrial safety trial data extend to 1 year, and observational data are reassuring for longer use.[12] Reassess benefit and tolerability periodically and follow the product-specific labeling.[12][3]

Monitoring​

  • No routine endometrial surveillance is required with low-dose vaginal estrogen[10][24]
  • Evaluate any postmenopausal bleeding with endometrial biopsy and/or TVUS[10]
  • For GSM symptom management with Estring, serum FSH and estradiol levels have not been shown useful.[39] NAMS reports that low-dose vaginal estrogen generally yields postmenopausal-range serum levels, with variable absorption from creams.[12] Among 20 postmenopausal patients with early hormone receptor-positive breast cancer receiving letrozole, 17 had serum estradiol above a sensitive assay's quantification limit during 12 weeks of 10 µg vaginal estradiol use.[44]
  • Reassess symptoms periodically to confirm ongoing benefit[21]

Systemic estrogen — what NOT to do​

  • Oral estrogen did not significantly reduce rUTIs versus placebo in three trials (RR 1.11; 95% CI 0.92–1.35)[13]
  • Systemic estrogen worsens urinary incontinence (WHI data)[10][16]
  • AGS Beers Criteria alternatives (2025) state: "Do not initiate systemic estrogen (e.g., oral, transdermal); consider deprescribing among older women already taking this medication; do not use systemic estrogen to manage incontinence (all types)"[11]
  • Women on systemic HT for vasomotor symptoms may still need additional vaginal estrogen for GSM symptoms[21]

Comparative summary​

IndicationVaginal estrogenSystemic estrogenOspemifenePrasterone (DHEA)
rUTI preventionEffective (RR 0.42); AUA Moderate Rec[1][13]Oral estrogen: no significant reduction (RR 1.11)[13]Not studiedNot studied
Vaginal dryness / dyspareuniaEffective (Level A)Effective, more systemic riskEffective (ACOG Level A)[23]Effective (Level B)[21]
Urgency / UUIPossible benefit with coexisting GSM[30][16][17]Worsens UINot studiedNot studied
SUIModest / inconsistent[18][19]Worsens UINot studiedNot studied
POPInsufficient evidence[20]Benefit for POP not established[20]Not studiedNot studied
Endometrial safetyReassuring short-term data; long-term limits[24]Progestogen requiredEndometrial agonist; boxed warning[35]Long-term data limited
Breast cancer safetyReassuring observational data; AI subgroup uncertainty[25][26]Generally contraindicated with a history of ER+ breast cancer[29]US label advises against use with known/suspected/history of breast cancer[35]Breast-cancer warning; not established safe[34]
Progestogen needed?No (low-dose formulations)[10]Yes (if uterus intact)NoNo

Evidence Summary​

IndicationEvidence levelKey source
rUTI preventionMeta-analysis of small RCTs (AUA: low strength) plus uncontrolled cohortChen 2021[13]; Tan-Kim 2023[14]; AUA/CUA/SUFU 2025[1]
Microbiome restoration mechanismRCT secondary analysis; small before-after studySrinivasan 2022[9]; Moore 2024[7]
Urgency / UUI improvementSystematic review; one small RCT with mixed outcomesChristmas 2023 SR[16]; Harncharoenkul 2026 RCT[17]
SUIEAU LE 1a for short-term improvement in postmenopausal women; its offer recommendation applies when vulvovaginal atrophy symptoms coexistWeber 2015[18]; Rahn 2023[19]; EAU 2026[40]
POPCochrane review (insufficient evidence)Taithongchai 2023[20]
Endometrial safetyShort-term trials/observational evidence; long-term limitationsAUA 2025[30]; ACOG141[24]
Breast cancer safetyLevel 2 (meta-analyses, cohorts)Beste 2025[25]; McVicker 2024[26]; Agrawal 2023[27]; Cold 2022[28]
FDA labeling revisionsProduct-specific regulatory actionNovember 2025 request; first six approvals February 2026[3]

Clinical Positioning​

  • Vaginal estrogen is recommended for rUTI prevention in peri- and postmenopausal women (AUA/CUA/SUFU 2025 Moderate Recommendation, Grade B; the 2025 AGS Beers Criteria alternatives panel calls it first-line in most older women[11]); RR 0.42 in the Chen meta-analysis and a 51.9% reduction in the uncontrolled Tan-Kim cohort; AUA's own pooled evidence is low strength.[1][13][14]
  • Route matters for rUTI prevention. In Chen's meta-analysis, five vaginal-estrogen randomized trials (n = 1,936) showed fewer recurrent UTIs versus placebo (RR 0.42, 95% CI 0.30–0.59), while three oral-estrogen trials (n = 2,766) did not show a statistically significant difference (RR 1.11, 95% CI 0.92–1.35).[13] WHI found more urinary incontinence with oral conjugated equine estrogen.[10][16] AUA/CUA/SUFU 2025 recommends vaginal estrogen for eligible peri- and postmenopausal women with rUTI and does not recommend systemic estrogen for rUTI prevention.[13][1]
  • Check the current product label. FDA revisions were product-specific.[3]
  • Formulation choice follows patient preference and clinical context. Inserts and rings offer more predictable low-dose exposure; consider dexterity, cost, local symptoms, and oncology input when relevant.[12][30]
  • In breast cancer survivors, vaginal estrogen is no longer reflexively contraindicated. Shared decision-making with oncology is appropriate, particularly in postmenopausal women with early-stage ER-positive breast cancer receiving adjuvant aromatase inhibitors, where the Cold 2022 Danish cohort found a recurrence association (adjusted RR 1.39) without increased mortality.[25][26][27][28]
  • No progestogen is routinely needed for endometrial protection with low-dose vaginal estrogen in short-term trials (AUA reviewed 8–36 weeks); long-term data remain limited. Always evaluate postmenopausal bleeding.[10][24]
  • Microbiome restoration is the proposed mechanism. In a 144-person secondary analysis of the Srinivasan 2022 RCT, 36/45 vaginal-estradiol users (80%) had Lactobacillus- or Bifidobacterium-dominant microbiota at 12 weeks versus 13/50 placebo users (26%).[9] In a 22-woman before-after microbiome study, baseline Lactobacillus deficiency was associated with the largest vaginal pH and microbial-community shifts.[7][9]
  • For GSM with OAB, consider vaginal estrogen as an adjunct. Do not delay appropriate bladder training, pelvic-floor therapy, or OAB medication solely to complete an estrogen trial.[30]
  • SUI with vulvovaginal atrophy. EAU 2026 strongly recommends offering vaginal oestrogen to postmenopausal women with SUI and atrophy symptoms, citing short-term SUI improvement (LE 1a); it also recommends supervised pelvic-floor muscle training as first-line SUI treatment.[40] Weber's 2015 systematic review reported fewer UI complaints with topical estrogen, while Rahn's preoperative prolapse trial did not detect a significant SUI difference at the preoperative visit.[18][19]
  • Counsel predictors of non-response. Age ≥75, higher baseline UTI frequency, incontinence, retention, and diabetes predict persistent UTIs despite vaginal estrogen.[14]

See Also​

References​

1. AUA/CUA/SUFU. Recurrent Uncomplicated Urinary Tract Infections in Women Guideline. Amended 2025. Official guideline.

2. Mainar LB, Nieto-Pascual L, Bravo EI, et al. "Safety of vaginal estrogen in breast cancer survivors: current evidence on systemic absorption and oncologic outcomes." Maturitas. 2026;208:108914. doi:10.1016/j.maturitas.2026.108914

3. US Food and Drug Administration. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." February 12, 2026. Official announcement.

4. Buck ES, Lukas VA, Rubin RS. "Effective prevention of recurrent UTIs with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause." Urology. 2021;151:31–36. doi:10.1016/j.urology.2020.05.058

5. Bodner-Adler B, Alarab M, Ruiz-Zapata AM, Latthe P. "Effectiveness of hormones in postmenopausal pelvic floor dysfunction — International Urogynecological Association Research and Development Committee Opinion." Int Urogynecol J. 2020;31(8):1577–1582. doi:10.1007/s00192-019-04070-0

6. Hirschberg AL. "Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptoms." Climacteric. 2025. doi:10.1080/13697137.2025.2514029

7. Moore KH, Ognenovska S, Chua XY, et al. "Change in microbiota profile after vaginal estriol cream in postmenopausal women with stress incontinence." Front Microbiol. 2024;15:1302819. doi:10.3389/fmicb.2024.1302819

8. Chang JG, Lewis MN, Wertz MC. "Managing menopausal symptoms: common questions and answers." Am Fam Physician. 2023;108(1):28–39. PMID 37440735

9. Srinivasan S, Hua X, Wu MC, et al. "Impact of topical interventions on the vaginal microbiota and metabolome in postmenopausal women: a secondary analysis of a randomized clinical trial." JAMA Netw Open. 2022;5(3):e225032. doi:10.1001/jamanetworkopen.2022.5032

10. Pinkerton JV. "Hormone therapy for postmenopausal women." N Engl J Med. 2020;382(5):446–455. doi:10.1056/NEJMcp1714787

11. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

12. North American Menopause Society. "The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society." Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609

13. Chen YY, Su TH, Lau HH. "Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials." Int Urogynecol J. 2021;32(1):17–25. doi:10.1007/s00192-020-04397-z

14. Tan-Kim J, Shah NM, Do D, Menefee SA. "Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women." Am J Obstet Gynecol. 2023;229(2):143.e1–143.e9. doi:10.1016/j.ajog.2023.05.002

15. Shen J, Song N, Williams CJ, et al. "Effects of low-dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis." Sci Rep. 2016;6:24380. doi:10.1038/srep24380

16. Christmas MM, Iyer S, Daisy C, et al. "Menopause hormone therapy and urinary symptoms: a systematic review." Menopause. 2023;30(6):672–685. doi:10.1097/GME.0000000000002187

17. Harncharoenkul P, Wattanayingcharoenchai R, Pongchaikul P, et al. "Efficacy of vaginal 17β-estradiol on the urinary storage symptoms in postmenopausal women: a randomized double-blind, placebo-controlled study." Sci Rep. 2026;16(1):12685. doi:10.1038/s41598-026-43359-1

18. Weber MA, Kleijn MH, Langendam M, et al. "Local oestrogen for pelvic floor disorders: a systematic review." PLoS One. 2015;10(9):e0136265. doi:10.1371/journal.pone.0136265

19. Rahn DD, Richter HE, Sung VW, Hynan LS, Pruszynski JE. "Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse." Am J Obstet Gynecol. 2023;229(3):309.e1–309.e10. doi:10.1016/j.ajog.2023.05.023

20. Taithongchai A, Johnson EE, Ismail SI, et al. "Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women." Cochrane Database Syst Rev. 2023;7:CD014592. doi:10.1002/14651858.CD014592.pub2

21. Crandall CJ, Mehta JM, Manson JE. "Management of menopausal symptoms: a review." JAMA. 2023;329(5):405–420. doi:10.1001/jama.2022.24140

22. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal treatments and vaginal moisturizers for genitourinary syndrome of menopause: a systematic review." Ann Intern Med. 2024;177(10):1400–1414. doi:10.7326/ANNALS-24-00610

23. American College of Obstetricians and Gynecologists. "Female sexual dysfunction: ACOG Practice Bulletin No. 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

24. American College of Obstetricians and Gynecologists. "ACOG Practice Bulletin No. 141: management of menopausal symptoms." Obstet Gynecol. 2014;123(1):202–216. doi:10.1097/01.AOG.0000441353.20693.78

25. Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. "Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks." Am J Obstet Gynecol. 2025;232(3):262–270.e1. doi:10.1016/j.ajog.2024.10.054

26. McVicker L, Labeit AM, Coupland CAC, et al. "Vaginal estrogen therapy use and survival in females with breast cancer." JAMA Oncol. 2024;10(1):103–108. doi:10.1001/jamaoncol.2023.4508

27. Agrawal P, Singh SM, Able C, et al. "Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer." Obstet Gynecol. 2023;142(3):660–668. doi:10.1097/AOG.0000000000005294

28. Cold S, Cold F, Jensen MB, et al. "Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study." J Natl Cancer Inst. 2022;114(10):1347–1354. doi:10.1093/jnci/djac112

29. American College of Obstetricians and Gynecologists. "Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

30. AUA/SUFU/AUGS. Genitourinary Syndrome of Menopause Guideline. 2025. Kaufman MR, Ackerman AL, Amin KA, et al. J Urol. 2025;214(3):242–250. doi:10.1097/JU.0000000000004589. Official guideline.

31. Laing AJ, Newson L, Simon JA. "Individual benefits and risks of intravaginal estrogen and systemic testosterone in the management of women in the menopause, with a discussion of any associated risks for cancer development." Cancer J. 2022;28(3):196–203. doi:10.1097/PPO.0000000000000598

32. Zuo SW, Mowers EE, Hem S, et al. "Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial." Obstet Gynecol. Published online July 27,2026. doi:10.1097/AOG.0000000000006376

33. Pfizer. Premarin Vaginal Cream US prescribing information. Label.

34. INTRAROSA prescribing information. DailyMed.

35. OSPHENA prescribing information. DailyMed.

36. ESTRACE (estradiol vaginal cream, 0.01%) prescribing information. DailyMed.

37. VAGIFEM (estradiol vaginal inserts) prescribing information. DailyMed.

38. IMVEXXY (estradiol vaginal inserts) prescribing information. DailyMed.

39. ESTRING (estradiol vaginal system) prescribing information. DailyMed.

40. European Association of Urology. Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (LUTS) Guidelines. Limited update, March 2026. EAU guidelines.

41. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management (NG123). NICE.

42. American Urogynecologic Society. "Practice Advisory: Removal of Black Box Warning Label from Topical Low-Dose Vaginal Estrogen Products." December 2025. AUGS practice advisory

43. Glenmark Pharmaceuticals Inc. Estradiol vaginal inserts, 10 mcg prescribing information. DailyMed, updated October 28, 2025. Label.

44. Faltinová M, Vehmanen L, Lyytinen H, et al. "Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial." Breast Cancer Res Treat. 2025;210(2):295–305. doi:10.1007/s10549-024-07564-8

45. Crandall CJ, Hovey KM, Andrews CA, et al. "Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study." Menopause. 2018;25(1):11–20. doi:10.1097/GME.0000000000000956

46. Vodegel EV, van Rest K, Speksnijder L, et al; EVA Study Group. "Vaginal Oestrogen Therapy for Postmenopausal Women Undergoing Prolapse Surgery: A Multicentre Double-Blind Randomised Placebo-Controlled Clinical Trial." BJOG. Published online August 28, 2026. doi:10.1111/1471-0528.70311. Full article.